Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia

This publication has 30 references indexed in Scilit:

• A large, 36 week study of the HDL-C raising effects and safety of simvastatin versus atorvastatin
  Atherosclerosis, 2000
• Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia
  The American Journal of Cardiology, 2000
• NK-104, a Newly Developed HMG-CoA Reductase Inhibitor, Suppresses Neointimal Thickening by Inhibiting Smooth Muscle Cell Growth and Fibronectin Production in Balloon-Injured Rabbit Carotid Artery
  The Japanese Journal of Pharmacology, 1998
• Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors
  Clinical Pharmacokinetics, 1997
• Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.
  Journal of Clinical Investigation, 1994
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
  The Lancet, 1994
• HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
  New England Journal of Medicine, 1988
• Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia
  Metabolism, 1987
• Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease.
  Circulation, 1981
• Serum lipid and lipoprotein levels in Japanese patients with familial hypercholesterolemia
  Atherosclerosis, 1979